Fulcrum Asset Management LLP bought a new position in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) during the third quarter, Holdings Channel.com reports. The fund bought 18,554 shares of the company’s stock, valued at approximately $3,775,000.
Other institutional investors also recently modified their holdings of the company. BlackRock Inc. acquired a new position in Moderna during the second quarter worth $2,142,877,000. Theleme Partners LLP acquired a new stake in shares of Moderna in the 2nd quarter worth about $564,272,000. Wellington Management Group LLP lifted its position in Moderna by 4.4% in the 2nd quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock valued at $172,384,000 after acquiring an additional 103,977 shares in the last quarter. First Trust Advisors LP lifted its position in Moderna by 59.3% in the 1st quarter. First Trust Advisors LP now owns 2,392,693 shares of the company’s stock valued at $121,549,000 after acquiring an additional 891,072 shares in the last quarter. Finally, Merck & Co. Inc. acquired a new position in Moderna during the 2nd quarter valued at about $161,642,545. 75.33% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
MRNA has been the subject of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Moderna in a report on Wednesday, September 9th. Deutsche Bank Aktiengesellschaft started coverage on Moderna in a report on Friday, August 28th. They issued a “hold” rating and a $125.00 target price on the stock. Piper Sandler reiterated an “overweight” rating and set a $305.00 price target (up from $230.00) on shares of Moderna in a report on Monday. JPMorgan Chase & Co. increased their price target on Moderna from $40.00 to $77.00 and gave the company an “underweight” rating in a research report on Friday, August 21st. Finally, Royal Bank Of Canada reiterated a “sector perform” rating and issued a $130.00 target price on shares of Moderna in a research note on Wednesday, August 19th. Six investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Moderna currently has a consensus rating of “Hold” and a consensus price target of $113.75.
View Our Latest Analysis on MRNA
Key Headlines Impacting Moderna
Here are the key news stories impacting Moderna this week:
- Positive Sentiment: Raised outlook and improved results: Moderna lifted its 2026 revenue-growth forecast to 15%–25% after a Q3 beat, citing lower costs and gains from respiratory vaccines. Moderna Q3 Earnings Call Highlights Raised Outlook and Oncology
- Positive Sentiment: Oncology pipeline milestone: Phase 3 data for personalized cancer therapy intismeran showed a 42% reduction in melanoma recurrence or death risk. Moderna aims to file with the FDA by year-end 2026, potentially setting up a decision in 2027. Can Moderna’s First Cancer Therapy Win FDA Approval in 2027?
- Positive Sentiment: Moderna’s collaboration with Tempus AI is among partnerships expected to generate about $192.5 million over five years, adding a potential source of revenue beyond vaccine sales. The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom
- Neutral Sentiment: Analysts raised one fair-value estimate from $135.84 to $145.42, reflecting improved Q3 execution and intismeran’s potential, while noting uncertainty about future COVID and oncology revenue. Moderna Stock Fair Value Rises After Intismeran Data And Q3 Beat
- Negative Sentiment: Revenue concentration and valuation risk: Nearly all revenue still comes from COVID-related products, leaving Moderna exposed to demand changes. Goldman Sachs raised its target to $195 but kept a neutral rating; that target and the cited fair-value estimate are both below the $269 price in the provided market data. Moderna’s Q3 Numbers May Have Seemed Impressive, but They Aren’t Enough to Make the Stock a Buy
Moderna Stock Up 5.8%
Shares of Moderna stock opened at $269.00 on Tuesday. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $280.80. The stock has a fifty day moving average price of $194.47 and a 200-day moving average price of $92.61. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09.
Moderna (NASDAQ:MRNA – Get Free Report) last issued its quarterly earnings results on Friday, November 6th. The company reported $0.38 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.10) by $1.48. The company had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $890.25 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm’s quarterly revenue was up 29.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.51) EPS. On average, analysts anticipate that Moderna, Inc. will post -6.11 earnings per share for the current year.
Insiders Place Their Bets
In other Moderna news, CFO Jamey Mock sold 34,836 shares of the business’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $134.49, for a total value of $4,685,093.64. Following the transaction, the chief financial officer directly owned 59,375 shares in the company, valued at $7,985,343.75. The trade was a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 39,145 shares of the business’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $220.72, for a total transaction of $8,640,084.40. Following the completion of the transaction, the president owned 1,636,565 shares in the company, valued at approximately $361,222,626.80. The trade was a 2.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 197,251 shares of company stock valued at $33,875,904. Company insiders own 10.80% of the company’s stock.
Moderna Profile
Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease.
The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases.
Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.
See Also
- Five stocks we like better than Moderna
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA – Free Report).
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.
